Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2009

View Archived Issues

4SC commences phase II 4SC-201 trial in hepatocellular carcinoma

Sitaxsentan treatment has multiple benefits in chronic kidney disease

Pfizer develops novel irreversible and reversible SARS 3CL protease inhibitors

Tumor hypoxia marker [18F]HX4 safe in phase I trial, phase II study planned

Novavax reports preclinical results from ferret study of H1N1 influenza VLP vaccine

Lpath completes enrollment in phase I study of iSonep in wet AMD

Roche reports results for first half 2009

GlaxoSmithKline claims tricyclic nitrogen-containing compounds as antibacterials

Array BioPharma describes Akt protein kinase inhibitors for cancer

Cathepsin K inhibitors identified at Amura for treating bone disorders

Solvay discloses bifeprunox derivatives for PD and other CNS-related disorders

LXR ligands for a variety of potential applications described by Wyeth

Abbott discloses new calpain inhibitors for neurological and other disorders

Focus of gamma-secretase inhibitor PF-3084014 shifts to cancer

Bristol-Myers Squibb identifies potent corticotropin-releasing factor-1 receptor antagonist

Light Sciences Oncology treats patients in phase II Aptocine trial in BPH

Peplin completes enrollment in final phase III ingenol mebutate trial in AK

COTI-2 plus Doxil superior to Doxil alone in animal ovarian cancer model

Amira submits IND for AM-461

Ablynx reports phase I results for subcutaneous administration of ALX-0681

Forest reports phase IIb results for oglemilast in COPD

Pfizer targets the type 1 glycine transporter with PF-3463275 for schizophrenia

Severe lung damage linked to long-term occupational nanoparticle exposure

InterMune and Roche initiate dosing in phase IIb clinical trial of ITMN-191

Gentium reports results from phase III defibrotide trial for sVOD

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 12, 2025
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...